News

Only 4 of the 20 most common cancers have a proven screening method.

Several novel chemoimmunotherapy combinations have risen to the forefront of treatment in triple-negative breast cancer.

Data from a recent analysis demonstrated that more than one in five people experienced depression or anxiety, either before or not long after receiving a blood cancer diagnosis, highlighting the need for further mental health screening in these individuals.

While there are multiple ways to create and deliver a survivorship care plan, clinicians should be thinking about these issues from the moment a patient is diagnosed.

The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.

Balazs Halmos, MD, discusses new advancements in lung cancer that are projected for 2021.

As the pandemic progresses and the long-term emotional effects of COVID-19 become clear, it is imperative to address the specific impact experienced by YA cancer survivors.

This is the second COVID-19 vaccine to be granted Emergency Use Authorization by the FDA.

The FDA has approved ponatinib for the treatment of patients with chronic-phase chronic myeloid leukemia that is resistant or intolerant to at least 2 prior kinase inhibitors.

The FDA has approved osimertinib (Tagrisso) for use as an adjuvant treatment following tumor resection in patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

The FDA has approved the oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (Orgovyx) as a treatment for patients with advanced prostate cancer.

The FDA approved selinexor (Xpovio) plus bortezomib and dexamethasone for the treatment of patients with myeloma who previously had at least 1 other treatment.

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

The FDA has approved rituximab-arrx for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

The state will be the 29th to allow nurse practitioners to practice without a physician.

The FDA has granted a fast track designation to devimistat (CPI-613) for the treatment of patients with acute myeloid leukemia (AML).

The FDA has approved margetuximab-cmkb (Margenza) plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.

Nurses want to be seen as leaders in their field, but their image in the public and in the media does not convey that yet. Two experts discuss how to change the “branding” of the profession.

Financial toxicity has been linked to increased mortality rates, but can be improved with financial intervention for patients.

Gastrointestinal (GI) adverse events (AEs) that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide, according to research presented at the 2020 San Antonio Breast Cancer Symposium.

A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.

The FDA issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of SARS-CoV-2 (which causes the coronavirus) for people aged 16 years or older.

Recent research highlighted the need for reliable information to address the educational and psychosocial needs of patients with newly diagnosed metastatic breast cancer.

BNT162b2 is the first vaccine recommended in the United States for the prevention of COVID-19.

Patients who experienced breakthrough CINV in their first chemotherapy cycle were more likely to have the adverse event in later cycles too, recent research found.

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

Oral azacitidine improved overall survival and relapse-free survival, while maintaining health-related quality of life in patients with acute myeloid leukemia.

Patients with cancer may be more susceptible to COVID-19. As oncology nurses await the approval of a vaccine, they shared their thoughts with Oncology Nursing News.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.